Royal Bank Of Canada Aptinyx Inc. Transaction History

Royal Bank Of Canada

  • $471 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.35 - $0.72 $151 - $311
432 New
432 $0
Q3 2021

Nov 15, 2021
SELL
$2.21 - $2.89 $20,526 - $26,842
-9,288 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$2.39 - $3.5 $22,198 - $32,508
9,288 New
9,288 $26,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email